PT2968434T - Composições de c1-inh e para uso na prevenção e no tratamento de distúrbios associados a deficiência de inibidor da c1-esterase - Google Patents

Composições de c1-inh e para uso na prevenção e no tratamento de distúrbios associados a deficiência de inibidor da c1-esterase

Info

Publication number
PT2968434T
PT2968434T PT147623433T PT14762343T PT2968434T PT 2968434 T PT2968434 T PT 2968434T PT 147623433 T PT147623433 T PT 147623433T PT 14762343 T PT14762343 T PT 14762343T PT 2968434 T PT2968434 T PT 2968434T
Authority
PT
Portugal
Prior art keywords
hae
prevention
treatment
hereditary angioedema
inh
Prior art date
Application number
PT147623433T
Other languages
English (en)
Portuguese (pt)
Inventor
Gallagher Cynthia
Ruddy Stephen
Cornell Manning Mark
Original Assignee
Shire Viropharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51538486&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2968434(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Viropharma Inc filed Critical Shire Viropharma Inc
Publication of PT2968434T publication Critical patent/PT2968434T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
PT147623433T 2013-03-15 2014-03-17 Composições de c1-inh e para uso na prevenção e no tratamento de distúrbios associados a deficiência de inibidor da c1-esterase PT2968434T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361791399P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
PT2968434T true PT2968434T (pt) 2017-09-18

Family

ID=51538486

Family Applications (2)

Application Number Title Priority Date Filing Date
PT147623433T PT2968434T (pt) 2013-03-15 2014-03-17 Composições de c1-inh e para uso na prevenção e no tratamento de distúrbios associados a deficiência de inibidor da c1-esterase
PT17177676T PT3290046T (pt) 2013-03-15 2014-03-17 Composições de c1-inh e para uso na prevenção e no tratamento de distúrbios associados a deficiência de inibidor da c1-esterase

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT17177676T PT3290046T (pt) 2013-03-15 2014-03-17 Composições de c1-inh e para uso na prevenção e no tratamento de distúrbios associados a deficiência de inibidor da c1-esterase

Country Status (30)

Country Link
US (9) US9616111B2 (enExample)
EP (3) EP3290046B1 (enExample)
JP (9) JP6184581B2 (enExample)
KR (4) KR20150135242A (enExample)
CN (2) CN111529708A (enExample)
AU (3) AU2014232912A1 (enExample)
BR (1) BR112015023207A8 (enExample)
CA (2) CA2904543C (enExample)
CY (2) CY1119419T1 (enExample)
DE (1) DE202014011208U1 (enExample)
DK (2) DK3290046T3 (enExample)
EA (1) EA201591278A1 (enExample)
ES (2) ES2713004T3 (enExample)
GB (1) GB2530921B (enExample)
HK (1) HK1250912B (enExample)
HR (2) HRP20171269T1 (enExample)
HU (2) HUE041837T2 (enExample)
IL (2) IL241549B (enExample)
LT (2) LT3290046T (enExample)
ME (2) ME02865B (enExample)
MX (3) MX389449B (enExample)
PL (2) PL2968434T3 (enExample)
PT (2) PT2968434T (enExample)
RS (2) RS58351B1 (enExample)
SG (2) SG10201707598QA (enExample)
SI (2) SI3290046T1 (enExample)
SM (2) SMT201700415T1 (enExample)
TR (1) TR201900319T4 (enExample)
WO (1) WO2014145519A2 (enExample)
ZA (3) ZA201507604B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6184581B2 (ja) 2013-03-15 2017-08-23 シャイア バイロファーマ インコーポレイテッド Ｃ１エステラーゼ抑制因子欠乏に関連する障害の予防及び治療のためのｃ１−ｉｎｈ組成物ならびに方法
KR102312817B1 (ko) 2013-11-22 2021-10-13 다케다 야쿠힌 고교 가부시키가이샤 C1-에스테라제 억제제를 사용한 장기 이식 환자에서의 항체-매개성 거부반응의 치료 방법
MX2017010323A (es) * 2015-02-20 2017-12-07 Csl Behring Gmbh Formulaciones farmaceuticas de inhibidor de esterasa c1.
CN108025047B (zh) * 2015-05-28 2021-11-19 康奈尔大学 腺相关病毒介导的c1ei递送作为用于血管性水肿的疗法
EP3377093B1 (en) 2015-11-19 2022-07-13 Takeda Pharmaceutical Company Limited Recombinant human c1 esterase inhibitor and uses thereof
US20190175683A1 (en) 2016-08-05 2019-06-13 Csl Behring Gmbh Pharmaceutical formulations of c1 esterase inhibitor
JP2019534240A (ja) * 2016-08-23 2019-11-28 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー Ｃ１エステラーゼ阻害剤欠乏に関連する遺伝性血管浮腫の急性発作を予防する方法
US12083171B2 (en) 2017-05-16 2024-09-10 Octapharma Ag C1-esterase inhibitor preparation
KR20210005549A (ko) 2018-02-28 2021-01-14 파밍 인텔렉츄얼 프라퍼티 비.브이. 전자간증의 치료 및 예방
WO2019166572A1 (en) 2018-02-28 2019-09-06 Pharming Intellectual Property B.V. Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor
US12397054B2 (en) 2018-06-22 2025-08-26 Junten Bio Co., Ltd. Antibody capable of inducing immune tolerance produced using cell mixture having complexed state, and induced lymphocyte or cell therapeutic agent and cell therapy method each using induced lymphocyte
TWI854983B (zh) 2018-06-22 2024-09-11 日商順天生化股份有限公司 誘導免疫耐受之抗體、被誘導之淋巴球、及使用被誘導之淋巴球之細胞治療劑治療方法
TWI832868B (zh) 2018-06-22 2024-02-21 日商順天生化股份有限公司 用於誘發感染性免疫耐受之組合物
WO2021124793A1 (ja) * 2019-12-16 2021-06-24 ニプロ株式会社 凝集防止剤ならびにそれを用いた医薬組成物および医療用デバイス
EP3895726A1 (en) 2020-04-17 2021-10-20 Pharming Intellectual Property BV Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress
US20240342258A1 (en) 2021-07-09 2024-10-17 Pharming Intellectual Property B.V. Using c1 esterase inhibitor to treat viral infection-related symptoms
KR20230046146A (ko) 2021-09-29 2023-04-05 주식회사 엘지에너지솔루션 배터리 제어 시스템 및 방법
WO2025090843A1 (en) * 2023-10-27 2025-05-01 Kansas State University Research Foundation Small-molecule inhibitors of c1s protease and classical complement pathway
CN119823254B (zh) * 2025-03-14 2025-06-03 深圳市卫光生物制品股份有限公司 一种c1酯酶抑制剂重组变体及其制备方法和应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304482A (en) 1989-03-06 1994-04-19 The Board Of Regents Of The University Of Texas System Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors
WO1992022320A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. C1 inhibitor variants and treating inflammatory response with c1 inhibitor
EP0716611B1 (en) 1993-09-01 2002-02-06 Stichting Sanquin Bloedvoorziening C1-esterase inhibitor to reduce myocardial injury during acute myocardial infarction
EP0868191A1 (en) 1995-12-18 1998-10-07 Stichting Sanquin Bloedvoorziening Potentiation of complement and coagulation inhibitory properties of c1-inhibitor.
AT409336B (de) 1999-12-22 2002-07-25 Baxter Ag Verfahren zur herstellung einer c1-esterase-inhibitor (c1-inh)-hältigen zusammensetzung
WO2001057079A2 (en) 2000-01-31 2001-08-09 Pharming Intellectual Property B.V. C1 inhibitor produced in the milk of transgenic mammals
US7067713B2 (en) * 2000-01-31 2006-06-27 Pharming Intellectual Property B.V. C1 Inhibitor produced in the milk of transgenic non-human mammals
ATE442862T2 (de) 2000-10-12 2009-10-15 Genentech Inc Niederviskose konzentrierte proteinformulierungen
DE10112617A1 (de) 2001-03-14 2002-10-02 Aventis Behring Gmbh Verwendung eines C1-Esterase-Inhibitors zur Verhinderung oder Verzögerung der Abstoßung von Xenotransplantaten in Säugetieren
WO2004034971A2 (en) 2002-09-25 2004-04-29 The Center For Blood Research, Inc. Methods for treating and preventing sepsis using modified c1 inhibitor or fragments thereof
WO2004110356A2 (en) 2003-05-15 2004-12-23 Cbr Institute For Biomedical Research, Inc. Methods for modulating cell-to-cell adhesion using an agonist of c1inh-type protein activity
USRE43691E1 (en) 2003-05-16 2012-09-25 Pharming Intellectual Property B.V. C1 inhibitor with short half-life transient treatment
US20060233776A1 (en) 2003-08-19 2006-10-19 Norbert Heimburger C1-inh as a drug for treating viruses pathogenic to humans
US8501705B2 (en) 2003-09-11 2013-08-06 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
EP1598428A1 (en) 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
EP2529746A1 (en) 2005-06-06 2012-12-05 Girish J. Kotwal Methods for treatment or prophylaxis of reperfusion injury
CN101340928B (zh) 2005-10-21 2011-12-21 催化剂生物科学公司 抑制补体激活的修饰的蛋白酶
CN105641688B (zh) * 2005-12-21 2020-06-09 法明知识产权股份有限公司 C1抑制剂在预防缺血-再灌注损伤中的应用
NZ568749A (en) 2005-12-21 2011-05-27 Pharming Intellectual Pty Bv Use of C1 inhibitor with reduced terminal sialic residues for the prevention of ischemia-reperfusion injury
US7837992B2 (en) 2006-06-22 2010-11-23 Beth Israel Deaconess Medical Center C-1 inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis
DK2109457T3 (en) 2007-02-12 2016-04-11 Csl Behring Gmbh THERAPEUTIC USE OF KAZAL TYPE SERINE PROTEASE INHIBITORS
NZ585702A (en) 2007-11-30 2013-08-30 Abbott Lab Protein formulations and methods of making same
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
US20100143325A1 (en) 2008-12-09 2010-06-10 Vascular Laboratory, Inc. Composition And Methods Involving Thrombolytic Agents
RS20120461A1 (sr) 2009-07-02 2013-06-28 Musc Foundation For Research Development Metode za stimulaciju regeneracije jetre
JP5911804B2 (ja) 2009-10-16 2016-04-27 オメロス コーポレーション Ｍａｓｐ−２依存性の補体活性化を阻害することによって播種性血管内凝固を処置するための方法
US9815876B2 (en) 2010-03-05 2017-11-14 Omeros Corporation Chimeric inhibitor molecules of complement activation
WO2011116291A1 (en) * 2010-03-18 2011-09-22 Thrombolytic Science International Production of human c1 inhibitor in human cells
WO2013013017A2 (en) * 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics
WO2013041677A1 (en) 2011-09-24 2013-03-28 Csl Behring Gmbh Combination therapy using immunoglobulin and c1-inhibitor
WO2013093027A1 (en) * 2011-12-22 2013-06-27 Csl Behring Gmbh Use of c1-inhibitor for the treatment of secondary edema of the central nervous system
EP2825204A1 (en) 2012-03-16 2015-01-21 Belrose Pharma Inc. Polymeric conjugates of c-1 inhibitors
CA2902841A1 (en) 2013-03-13 2014-10-02 Creatics Llc Methods and compositions for detecting pancreatic cancer
JP6184581B2 (ja) * 2013-03-15 2017-08-23 シャイア バイロファーマ インコーポレイテッド Ｃ１エステラーゼ抑制因子欠乏に関連する障害の予防及び治療のためのｃ１−ｉｎｈ組成物ならびに方法
JP6889626B2 (ja) * 2017-06-29 2021-06-18 トキコシステムソリューションズ株式会社 燃料供給システム
JP6935245B2 (ja) * 2017-06-29 2021-09-15 大和ハウス工業株式会社 収容ラック

Also Published As

Publication number Publication date
US20170224788A1 (en) 2017-08-10
US20190160158A1 (en) 2019-05-30
US20190160157A1 (en) 2019-05-30
EP3290046B1 (en) 2019-01-02
JP6473535B2 (ja) 2019-02-20
ZA201507604B (en) 2018-05-30
LT2968434T (lt) 2017-09-25
JP6473534B2 (ja) 2019-02-20
CA2904543C (en) 2019-10-08
LT3290046T (lt) 2019-03-12
EA201591278A1 (ru) 2016-03-31
SG11201507616VA (en) 2015-10-29
JP6877470B2 (ja) 2021-05-26
HRP20190270T1 (hr) 2019-04-05
ME02865B (me) 2018-04-20
IL276153B (en) 2022-06-01
CY1121653T1 (el) 2020-07-31
TR201900319T4 (tr) 2019-02-21
JP2017105847A (ja) 2017-06-15
KR20150135242A (ko) 2015-12-02
AU2020203183B2 (en) 2022-06-02
JP6184581B2 (ja) 2017-08-23
CN111529708A (zh) 2020-08-14
SMT201700415T1 (it) 2017-11-15
GB201519921D0 (en) 2015-12-23
ME03326B (me) 2019-10-20
EP2968434B1 (en) 2017-06-28
KR20220070049A (ko) 2022-05-27
HRP20171269T1 (hr) 2017-11-03
JP2019073544A (ja) 2019-05-16
NZ751555A (en) 2021-07-30
SI3290046T1 (sl) 2019-04-30
JP2018119000A (ja) 2018-08-02
SG10201707598QA (en) 2017-10-30
EP3508213A1 (en) 2019-07-10
ES2713004T3 (es) 2019-05-17
JP2019073546A (ja) 2019-05-16
MX389449B (es) 2025-03-20
BR112015023207A8 (pt) 2018-01-23
EP2968434A4 (en) 2016-03-02
US20180085441A1 (en) 2018-03-29
MX373965B (es) 2020-07-13
US11534482B2 (en) 2022-12-27
IL276153A (en) 2020-09-30
CY1119419T1 (el) 2018-03-07
NZ710730A (en) 2021-07-30
US10130690B2 (en) 2018-11-20
PT3290046T (pt) 2019-02-18
US20180110844A1 (en) 2018-04-26
KR20210129267A (ko) 2021-10-27
AU2018229558A1 (en) 2018-10-04
AU2020203183A1 (en) 2020-06-04
RS58351B1 (sr) 2019-03-29
EP3290046A1 (en) 2018-03-07
MX2021011946A (es) 2021-11-17
EP2968434A2 (en) 2016-01-20
HUE036224T2 (hu) 2018-06-28
CN105517559A (zh) 2016-04-20
AU2014232912A1 (en) 2015-09-03
BR112015023207A2 (pt) 2017-11-21
DE202014011208U1 (de) 2018-08-23
US9616111B2 (en) 2017-04-11
PL2968434T3 (pl) 2018-01-31
JP6877472B2 (ja) 2021-05-26
JP6877471B2 (ja) 2021-05-26
US20200261556A1 (en) 2020-08-20
US10080788B2 (en) 2018-09-25
PL3290046T3 (pl) 2019-05-31
SMT201900141T1 (it) 2019-05-10
DK2968434T3 (en) 2017-09-11
JP6422520B2 (ja) 2018-11-14
JP2018119002A (ja) 2018-08-02
JP2021088599A (ja) 2021-06-10
RS56285B1 (sr) 2017-12-29
US10201595B2 (en) 2019-02-12
US20180110843A1 (en) 2018-04-26
KR20210021146A (ko) 2021-02-24
WO2014145519A3 (en) 2014-12-31
IL241549B (en) 2020-08-31
HUE041837T2 (hu) 2019-05-28
HK1250912B (en) 2020-01-10
CA2904543A1 (en) 2014-09-18
JP6473536B2 (ja) 2019-02-20
JP2018119001A (ja) 2018-08-02
WO2014145519A2 (en) 2014-09-18
JP2016516073A (ja) 2016-06-02
DK3290046T3 (en) 2019-03-18
MX2015011281A (es) 2016-03-03
GB2530921A (en) 2016-04-06
GB2530921B (en) 2017-09-20
MX2020004724A (es) 2022-01-18
HK1220403A1 (en) 2017-05-05
AU2018229558B2 (en) 2020-03-05
ES2639833T3 (es) 2017-10-30
SI2968434T1 (sl) 2017-11-30
KR102579789B1 (ko) 2023-09-15
CA3054718A1 (en) 2014-09-18
US11364288B2 (en) 2022-06-21
JP2019073545A (ja) 2019-05-16
US20160015795A1 (en) 2016-01-21
US20180153972A1 (en) 2018-06-07
US10105423B2 (en) 2018-10-23
ZA201806793B (en) 2020-01-29
ZA201706929B (en) 2019-05-29
KR102430453B1 (ko) 2022-08-05

Similar Documents

Publication Publication Date Title
LT2968434T (lt) C1-inh kompozicijos, skirtos panaudoti paveldimos angiodemos prevencijai ir gydymui
IL246864B (en) Plasma kallikrein-binding proteins and their uses in the treatment of hereditary angioedema
BR112015001838A2 (pt) composições de inibidor de efluxo e métodos de tratamento utilizando o mesmo.
PT2945642T (pt) Proteína do fator 1 para utilização no tratamento ou prevenção de doenças
EP3052510A4 (en) Methods and compositions for treating and/or preventing mucositis
EP3038474A4 (en) Nutraceutical combination for prevention and treatment of type 2 diabetes
IL241823B (en) Preparations containing novyi .c and their uses for the treatment of cancerous tumors
PL2968478T3 (pl) Kompozycje i sposoby do leczenia karboksyhemoglobinemii
EP2905337A4 (en) AMPHIREGULIN SPECIFIC DOUBLE HELIX OLIGO RNA, DOUBLE HELIX OLIGO RNA STRUCTURE WITH THE DOUBLE HELIX OLIGO RNA AND COMPOSITION FOR PREVENTING OR TREATING RESPIRATORY DISEASES THEREWITH
EP2994156A4 (en) Compounds, compositions and methods for the treatment of diseases through inhibiting tgf- activity
IL235035A0 (en) A preparation to prevent an effect on blood vessels in the treatment of blood loss and anemia
PL3041459T3 (pl) Kompozycje przydatne w zapobieganiu lub leczeniu raka skóry
SMT202100490T1 (it) Composizione comprendente geraniolo e zenzero secco per l'uso nel trattamento della sindrome del colon irritabile
GB201513543D0 (en) Compositions for use in the treatment of diabetes
PL2862576T3 (pl) Drobnoustroje i zawierające je kompozycje do stosowania do leczenia lub profilaktyki zapalenia sutka
GB2510477B (en) Formulations for use in the treatment of chronic fatigue and associated conditions, etc
IL247616B (en) Centrally acting acetylcholinesterase inhibitors for the prevention/or treatment of chemically induced neurodegenerative diseases and their symptoms, and corresponding compositions, uses, methods and kit
AU2013904048A0 (en) Compositions and methods for the prevention and/or treatment of neurogenic inflammation and/or infla
TH1401007825A (th) องค์ประกอบที่มีน้ำชาสำหรับการป้องกันการเปลี่ยนตามวัยของผิวหนัง